SCHEMBL28484797

SCHEMBL28484797

CC(C)(C)OC(=O)N1[C@@]2(C)CC[C@]1(C)CC(N)C2

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM1A O60341 2/20 0.39
CHRM2 P08172 1/20 0.36
CHRM1 P11229 1/20 0.36
CHRM3 P20309 1/20 0.36
EPHX2 P34913 1/20 0.35
USP2 O75604 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
CTSK P43235 1/20 0.34
NR1H2 P55055 1/20 0.33
HPGD P15428 1/20 0.33
SPHK1 Q9NYA1 1/20 0.32
GRIN2B Q13224 1/20 0.32
GRIN2C Q14957 1/20 0.32
BUB1 O43683 1/20 0.31
KDM4E B2RXH2 1/20 0.31
MAPT P10636 1/20 0.31
THRB P10828 1/20 0.31
RECQL P46063 1/20 0.31
EPHX1 P07099 1/20 0.31
GPR119 Q8TDV5 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25176823 1.00 KDM1A (0.39) KDM1ACHRM2CHRM1CHRM3EPHX2
SCHEMBL22214267 1.00 KDM1A (0.39) KDM1ACHRM2CHRM1CHRM3EPHX2
SCHEMBL30277219 0.85 CHRM2 (0.44) KDM1ACHRM2CHRM1CHRM3EPHX2
SCHEMBL1964183 0.83 KDM1A (0.38) KDM1ACHRM2CHRM1CHRM3EPHX2
SCHEMBL22313086 0.81 KDM1A (0.35) KDM1ACHRM2CHRM1CHRM3EPHX2
SCHEMBL25246687 0.79 USP2 (0.36) KDM1ACHRM2CHRM1CHRM3EPHX2
SCHEMBL29431708 0.79 USP2 (0.38) KDM1ACHRM2CHRM1CHRM3EPHX2
SCHEMBL16414603 0.79 NR1H2 (0.40) CHRM2CHRM1CHRM3EPHX2USP2
SCHEMBL16419901 0.79 CHRM2 (0.35) KDM1ACHRM2CHRM1CHRM3EPHX2
SCHEMBL24248698 0.78 KDM1A (0.34) KDM1ACHRM2CHRM1CHRM3EPHX2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024182747-A2 COMPOUNDS AND METHODS FOR MODULATING SPLICING REMIX THERAPEUTICS INC. (US) 2024-09-06 WO disclosed
WO-2024131942-A1 CYCLOPROPANE TLR7 AND TLR8 INHIBITOR, PREPARATION METHOD THEREFOR, AND USE THEREOF 上海深势唯思科技有限责任公司 2024-06-27 WO disclosed
CN-118239959-A Cyclopropane TLR7 and 8 inhibitor and preparation method and application thereof 上海深势唯思科技有限责任公司 2024-06-25 CN disclosed
CN-111194215-B Methods and compositions for modulating splicing 斯基霍克疗法公司 2024-03-01 CN disclosed
CN-111499615-B Methods and compositions for modulating splicing 斯基霍克疗法公司 2024-02-02 CN disclosed
US-11603531-B1 Methods and compositions for modulating splicing SKYHAWK THERAPEUTICS, INC. (US) 2023-03-14 US disclosed
US-20230059865-A1 METHODS AND COMPOSITIONS FOR MODULATING SPLICING SKYHAWK THERAPEUTICS, INC. 2023-02-23 US disclosed
US-20220403383-A1 METHODS AND COMPOSITIONS FOR MODULATING SPLICING SKYHAWK THERAPEUTICS, INC. 2022-12-22 US disclosed
US-11434489-B1 Methods and compositions for modulating splicing SKYHAWK THERAPEUTICS, INC. (US) 2022-09-06 US disclosed
US-11326165-B1 Methods and compositions for modulating splicing SKYHAWK THERAPEUTICS, INC. (US) 2022-05-10 US disclosed
CN-111499615-A Methods and compositions for modulating splicing 斯基霍克疗法公司 2020-08-07 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11603531-B1 Methods and compositions for modulating splicing RBM17, SF3B1, SNRPA1 KDM1A 3266/4885CHRM2 4724/4885CHRM1 4689/4885
US-11326165-B1 Methods and compositions for modulating splicing RBM17, SF3B1, SNRPA1 KDM1A 3266/4885CHRM2 4724/4885CHRM1 4689/4885
US-20220403383-A1 METHODS AND COMPOSITIONS FOR MODULATING SPLICING RBM17, SF3B1, SNRPA1 KDM1A 3266/4885CHRM2 4724/4885CHRM1 4689/4885
US-11434489-B1 Methods and compositions for modulating splicing RBM17, SF3B1, SNRPA1 KDM1A 3266/4885CHRM2 4724/4885CHRM1 4689/4885
US-20230059865-A1 METHODS AND COMPOSITIONS FOR MODULATING SPLICING RBM17, SF3B1, SNRPA1 KDM1A 3266/4885CHRM2 4724/4885CHRM1 4689/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.